



Wes Moore, Governor · Aruna Miller, Lt. Governor · Laura Herrera Scott, M.D., M.P.H., Secretary

MARYLAND MEDICAL ASSISTANCE PROGRAM
MCO Transmittal No. 230
Physician Transmittal No. 173
Behavioral Health Services Organization Transmittal No. 28
November 20, 2024

TO: Managed Care Organizations
 Behavioral Health Administrative Services Organization
 Physicians
 Pain Clinics

Sandra E. Kick

FROM: Sandra Kick, Director
 Medical Benefits Management

RE: Payment Responsibility for Pain Management Clinic Toxicology Testing
 Effective January 1, 2025

NOTE: **Please ensure that the appropriate staff members in your organization are informed of the content of this transmittal.**

Effective January 1, 2025, Maryland Medicaid (the Department) will require providers rendering toxicology screenings for the purpose of pain management to submit claims for drug testing codes for on HealthChoice participants to HealthChoice managed care organizations (MCOs).

With the launch of Carelon Behavioral Health as the new BHASO vendor on January 1, 2025, the Department is updating this policy to reduce administrative burden and end split billing for pain management providers. This policy update is consistent with existing regulations under COMAR 10.67.08.02 which designate the MCO as responsible for these tests when rendered by a primary care or other somatic care provider.

Effective January 1, 2025, providers should bill the following procedure codes to the participant's MCO:

Procedure Code	Description	Fee-for-Service Rate
80305	Drug test(s), presumptive, any number of drug classes; any number of devices or procedures, (eg, immunoassay) capable of being read by direct optical observation only (eg, dipsticks, cups, cards, cartridges), includes sample validation when performed, per date of service	\$10.02
80306	Drug test(s), presumptive, any number of drug classes; any number of devices or procedures, (eg, immunoassay) read by instrument-assisted direct optical observation (eg, dipsticks, cups, cards, cartridges), includes sample validation when performed, per date of service	\$10.02
80307	Drug test(s), presumptive, any number of drug classes; any number of devices or procedures by instrumented chemistry analyzers (eg, immunoassay, enzyme assay, TOF, MALDI, LDTD, DESI, DART, GHPC, GC mass spectrometry), includes sample validation when performed, per date of service	\$49.49
G0480	Per day, 1-7 drug class(es), including metabolite(s) if performed.	\$90.97
G0481	Per day, 8-14 drug class(es), including metabolite(s) if performed.	\$124.49

The Department has updated the provider enrollment addendum for providers to add pain management specialty to their enrollment. The updated addendum is available on the ePREP Provider Agreement and Application Addenda website at:

<https://health.maryland.gov/mmcp/provider/Pages/eprepforms.aspx>.

Please note that specialty behavioral health providers billing for office visits related to substance use disorder treatment will continue to bill the BHASO for any corresponding drug testing.

For questions related to this transmittal, please contact mdh.healthchoiceprovider@maryland.gov email.